Back to Depression And Anxiety
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01849367

NCT01849367
Completed Phase 2 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with a Major Depressive Episode according to standard psychiatric guidelines (DSM-IV).
  • Your depression has been rated as moderately severe or worse, based on a standard scoring tool called the MADRS (a score of 20 or more).

Who may not be able to join:

  • You have ever been diagnosed with a psychotic disorder, or currently have (or have had in the past year) an eating disorder or post-traumatic stress disorder (PTSD), or have ever been diagnosed with obsessive compulsive disorder or intellectual disability.
  • You have had problems with drug or alcohol abuse or dependence in the last 3 months (not including nicotine or caffeine).
  • Your depression has not responded to electroconvulsive therapy (ECT) during this current episode of depression.
  • You regularly take medication from the benzodiazepine family (such as sleeping tablets or anti-anxiety medication) and it would not be safe for you to stop taking it.
  • Your condition requires very urgent treatment because of severe weight loss, psychosis, or a high risk of suicide.
  • You have a neurological condition or have had a brain injury (such as a recent stroke) that could make the treatment risky for you.
  • You have any metal in your skull, holes or defects in your skull, or cuts, sores, or a rash on your scalp where the treatment pads would be placed.
  • You are pregnant, or are of childbearing age, sexually active, and not using a reliable form of contraception (a urine pregnancy test will be required).
  • You are not fluent in English.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
The University of New South Wales
Registry
clinicaltrials_gov
Start date
1 May 2013
Est. completion
1 July 2015

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Montgomery Asberg Depression Rating Scale for Depression (MADRS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov